Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPO Update: With No New Offerings, Kadmon Steals The Spotlight

Executive Summary

Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.


Related Content

IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
IPO Update: Haircuts Needed To Price Biotech Offerings
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals
Waksal's Kadmon acquires Three Rivers


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts